Literature DB >> 25304847

Staging and evaluation of neoadjuvant chemotherapy response with ¹⁸F-FDG PET/CT in NUT-midline carcinoma in a child: a case report and review of the literature.

E Ciftci1, U Demirsoy2, Y Anik3, G Gorur4, F Corapcioglu5, H Demir6.   

Abstract

NUT midline carcinoma (NMC) is a newly defined and lethal cancer with aggressive course. It mostly affects children and young adults. Diagnosis is confirmed with the evidence of BRD4-NUT mutation on the chromosome 15q14 by fluorescence in situ hybridization. Use of (18)F-FDG PET/CT in NMC patients is very limited in the literature. In this report, we describe a 7-year-old boy with the diagnosis of NMC who was scanned with (18)F-FDG PET/CT for staging and treatment response evaluation after the chemotherapy. It was disseminated and had moderate FDG avidity in the initial scan and showed progression after 4 cycles of chemotherapy. We also reviewed the literature related to (18)F-FDG PET/CT in staging and assessment of chemotherapy response of NMC.
Copyright © 2014 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

Entities:  

Keywords:  (18)F-FDG PET/CT; (18)F-FDG PET/TAC; Carcinoma de línea media – NUT; Children; Evaluación de la respuesta; NUT midline carcinoma; Niños; Response evaluation

Mesh:

Substances:

Year:  2014        PMID: 25304847     DOI: 10.1016/j.remn.2014.08.007

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  2 in total

Review 1.  Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases.

Authors:  Prashanth Giridhar; Supriya Mallick; Lakhan Kashyap; Goura Kishor Rath
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-01-22       Impact factor: 2.503

2.  NUT midline carcinoma mimicking a germ cell tumor: a case report.

Authors:  Yohei Harada; Takafumi Koyama; Kengo Takeuchi; Kazufusa Shoji; Kazuei Hoshi; Yu Oyama
Journal:  BMC Cancer       Date:  2016-11-17       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.